On (b)(6) 2016 the suspect medical device lot number was updated.This is documented.Further investigation of the customer issue included a review of the complaint text, in-house testing, a search for similar complaints, a batch record review and a review of labeling.Return material was not available from the customer.An accuracy testing protocol was executed; testing met the acceptance criteria and determined the reagent is performing acceptably.Tracking and trending did not identify an adverse trend for the lot in question.No issues were identified which would indicate a product deficiency from the batch record review.Labeling was reviewed and found to be adequate.Based on the available information no product deficiency and no malfunction of the architect insulin reagent, list (b)(4), lot 60121lp76, was identified.
|
Correction to the evaluation summary previously documented.The device evaluation was reassessed and concluded that a malfunction occurred, therefore, the documentation of no malfunction is inaccurate.However, no systemic issue or product deficiency was identified.
|